Several brokerages have updated their recommendations and price targets on shares of Progyny (NASDAQ: PGNY) in the last few weeks:
- 11/9/2026 – Progyny had its price target raised by JPMorgan Chase & Co. from $30.00 to $35.00. They now have a “neutral” rating on the stock.
- 11/8/2026 – Progyny was upgraded by Wall Street Zen from “buy” to “strong-buy”.
- 11/5/2026 – Progyny had its price target raised by Wells Fargo & Company from $37.00 to $38.00. They now have an “overweight” rating on the stock.
- 11/5/2026 – Progyny had its “market outperform” rating reaffirmed by Citigroup.
- 11/5/2026 – Progyny had its price target raised by Leerink Partners from $37.00 to $38.00. They now have an “outperform” rating on the stock.
- 11/5/2026 – Progyny had its price target raised by Citizens Jmp from $33.00 to $38.00. They now have a “market outperform” rating on the stock.
- 11/5/2026 – Progyny had its price target raised by Cantor Fitzgerald from $31.00 to $35.00. They now have an “overweight” rating on the stock.
- 10/31/2026 – Progyny was downgraded by Wall Street Zen from “strong-buy” to “buy”.
- 10/19/2026 – Progyny was downgraded by Zacks Research from “strong-buy” to “hold”.
- 10/8/2026 – Progyny was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
- 9/30/2026 – Progyny is now covered by Wells Fargo & Company. They set an “overweight” rating and a $37.00 price target on the stock.
- 9/19/2026 – Progyny was upgraded by Wall Street Zen from “buy” to “strong-buy”.
Progyny Trading Up 2.7%
Shares of NASDAQ:PGNY traded up $0.97 during midday trading on Monday, hitting $37.15. The company had a trading volume of 1,086,840 shares, compared to its average volume of 1,062,968. Progyny, Inc. has a 12 month low of $16.10 and a 12 month high of $37.20. The firm has a fifty day simple moving average of $28.48 and a 200 day simple moving average of $24.87. The stock has a market cap of $2.74 billion, a price-to-earnings ratio of 34.08, a PEG ratio of 1.70 and a beta of 0.97.
Progyny (NASDAQ:PGNY – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.21. Progyny had a return on equity of 19.82% and a net margin of 6.80%. The business had revenue of $341.25 million during the quarter, compared to the consensus estimate of $340.76 million. During the same quarter in the prior year, the company posted $0.15 earnings per share. The firm’s revenue was up 8.9% on a year-over-year basis. Equities analysts forecast that Progyny, Inc. will post 1.43 EPS for the current fiscal year.
Insider Activity at Progyny
In related news, CFO Mark S. Livingston sold 2,139 shares of the stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $30.00, for a total value of $64,170.00. Following the sale, the chief financial officer directly owned 70,314 shares in the company, valued at $2,109,420. This trade represents a 2.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Allison Swartz sold 3,903 shares of Progyny stock in a transaction that occurred on Wednesday, September 23rd. The stock was sold at an average price of $26.10, for a total transaction of $101,868.30. Following the transaction, the executive vice president directly owned 75,816 shares in the company, valued at $1,978,797.60. The trade was a 4.90% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 630,072 shares of company stock worth $22,363,084. 9.90% of the stock is owned by company insiders.
Progyny, Inc. provides fertility and family-building benefits to employers and their employees. Its services are designed to help members navigate care options, access fertility specialists and receive support throughout treatment. The company’s offerings include coverage for treatments such as in vitro fertilization and egg freezing, along with fertility medications through its pharmacy benefit. Progyny also supports other family-building paths, including adoption and surrogacy, depending on the plan selected by an employer.
Read More
- Five stocks we like better than Progyny
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Progyny Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny Inc and related companies with MarketBeat.com's FREE daily email newsletter.
